Published in J Virol on February 01, 1997
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol (1997) 2.08
Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 2.06
Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol (1999) 1.75
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol (2005) 1.73
Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol (1998) 1.69
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol (2005) 1.53
Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. J Virol (1999) 1.20
The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. J Virol (1998) 1.19
Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5. J Virol (1999) 1.14
Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J Virol (2000) 1.14
Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol (1997) 1.13
CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry. J Virol (1997) 1.12
Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J Virol (2000) 1.07
Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol (2006) 1.07
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol (2003) 0.95
CD4-independent human immunodeficiency virus infection involves participation of endocytosis and cathepsin B. PLoS One (2011) 0.93
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol (2007) 0.93
A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway. Virology (2005) 0.92
CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain. J Virol (2001) 0.91
CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. J Virol (2000) 0.89
Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide. J Virol (2006) 0.86
CD4-independent entry and replication of simian immunodeficiency virus in primary rhesus macaque astrocytes are regulated by the transmembrane protein. J Virol (2005) 0.83
A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. Gene Ther (2010) 0.83
Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells. J Virol (1997) 0.82
Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery. J Drug Deliv (2012) 0.78
Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. J Virol (2016) 0.78
Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles. J Genet Syndr Gene Ther (2011) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 8.26
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1989) 7.34
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol (1992) 5.19
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell (1985) 4.84
The CD4 antigen: physiological ligand and HIV receptor. Cell (1988) 4.42
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol (1991) 4.39
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res (1984) 3.67
Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology (1991) 3.54
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens. Proc Natl Acad Sci U S A (1979) 3.29
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
SIV adaptation to human cells. Nature (1989) 3.09
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol (1991) 3.07
Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1992) 3.02
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science (1991) 2.77
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol (1992) 2.59
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol (1992) 2.51
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J Virol (1992) 2.36
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol (1993) 2.34
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Infection of brain-derived cells with the human immunodeficiency virus. J Virol (1987) 2.01
Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus). Biochem Biophys Res Commun (1984) 1.94
West African HIV-2-related human retrovirus with attenuated cytopathicity. Science (1988) 1.86
Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. J Virol (1987) 1.84
Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses (1994) 1.83
Misidentified cell. Nature (1989) 1.81
Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J Virol (1993) 1.81
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (1989) 1.80
Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses (1992) 1.60
CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. Nat Med (1995) 1.59
HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology (1994) 1.56
Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J Virol (1990) 1.53
Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry. Virology (1993) 1.45
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res Hum Retroviruses (1993) 1.28
Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J Virol (1994) 1.24
Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4. J Virol (1991) 1.20
HIV vaccines. Back to primary school. Nature (1995) 1.15
Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism. J Virol (1995) 1.05
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J Virol (1995) 1.03
Reduced glycosylation of human cell lines increases susceptibility to CD4-independent infection by human immunodeficiency virus type 2 (LAV-2/B). J Virol (1995) 0.99
Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol (1996) 0.98
Amino acid changes in the fourth conserved region of human immunodeficiency virus type 2 strain HIV-2ROD envelope glycoprotein modulate fusion. J Virol (1993) 0.94
Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4. J Acquir Immune Defic Syndr (1991) 0.87
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol (1999) 2.36
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol (1999) 1.90
Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis (1998) 1.79
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology (1993) 1.74
Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol (1999) 1.66
Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med (2000) 1.64
Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer (1998) 1.61
Adult T-cell leukaemia/lymphoma in Brazil and its relation to HTLV-I. Lancet (1990) 1.47
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol (2000) 1.44
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS (1998) 1.34
Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer (1989) 1.31
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
The human herpesvirus-8 ORF 57 gene and its properties. J Gen Virol (1999) 1.25
Risk factors for Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer (1998) 1.25
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. AIDS (1999) 1.17
Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. J Immunol (1984) 1.12
Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol (2001) 1.10
Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol (1999) 1.09
Reduced seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV), human herpesvirus 8 (HHV8), related to suppression of Anopheles density in Italy. Med Vet Entomol (2003) 1.08
Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR. J Virol (1997) 1.07
Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses (1993) 1.07
Origin of AIDS. Lancet (1992) 1.07
Isolation of a new foamy retrovirus from orangutans. J Virol (1994) 1.06
Envelope gene-derived recombinant peptide in the serodiagnosis of human immunodeficiency virus infection. Lancet (1986) 1.06
Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol (1987) 1.06
Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood (2000) 1.05
Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol (2008) 1.03
Evidence for horizontal and not vertical transmission of human herpesvirus 8 in children born to human immunodeficiency virus-infected mothers. Pediatr Infect Dis J (1999) 1.02
Recombination in human herpesvirus-8 strains from Uganda and evolution of the K15 gene. J Gen Virol (2001) 1.01
Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Transplantation (1999) 1.00
No increased human herpesvirus 8 seroprevalence in patients with HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr (2001) 0.99
Reduced glycosylation of human cell lines increases susceptibility to CD4-independent infection by human immunodeficiency virus type 2 (LAV-2/B). J Virol (1995) 0.99
HHV-8 and multiple myeloma in the UK. Lancet (1997) 0.97
A murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene. Virology (1991) 0.96
HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett (1989) 0.96
Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73. Proc Natl Acad Sci U S A (2000) 0.94
Multifactorial basis of C3b receptor reactivity. Mol Immunol (1984) 0.94
Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N Engl J Med (1998) 0.94
Comparison of Western blot (immunoblot) based on recombinant-derived p41 with conventional tests for serodiagnosis of human immunodeficiency virus infections. J Clin Microbiol (1988) 0.94
Transforming properties of the HTLV-I tax gene. Cancer Cells (1990) 0.91
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of Kaposi's sarcoma. Curr Opin Infect Dis (1998) 0.91
Human complement factor H: isolation of cDNA clones and partial cDNA sequence of the 38-kDa tryptic fragment containing the binding site for C3b. Eur J Immunol (1986) 0.90
Structural and functional relationships among receptors and regulators of the complement system. Mol Immunol (1988) 0.90
Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol (1989) 0.90
Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology (1988) 0.90
Human herpesvirus 8 infection occurs following adolescence in the United States. J Infect Dis (1997) 0.89
Mapping of the properdin-binding site in the third component of complement. Biochem J (1984) 0.89
CD26 antigen and HIV fusion? Science (1994) 0.89
Rhadinoviruses (gamma2-herpesviruses) of Old World primates: models for KSHV/HHV8-associated disease? AIDS (2000) 0.88
Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis (1999) 0.88
Kaposi's sarcoma. A finger on the culprit. Nature (1995) 0.88
HIV. Cyclophilins unfold the Gag? Nature (1993) 0.88
Antigenic relationship between the alpha-chain of C3, a leucocyte-surface antigen involved in the activation of phagocytic cells, and a 50,000 MW B-cell antigen. Immunology (1985) 0.88
Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells. J Acquir Immune Defic Syndr (1990) 0.87
Prevalence of infection with human herpesvirus 8/Kaposi's sarcoma herpesvirus in rural South Africa. S Afr Med J (1999) 0.86
Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells. Oncogene (2012) 0.86
Coupling of C3b to erythrocytes by disulfide bond formation: preparation of EC3b for hemolytic and complement receptor assays. J Immunol Methods (1983) 0.85
Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor. Immunology (1988) 0.85
The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function. FEBS Lett (1998) 0.85
Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis (1999) 0.85
The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia (1997) 0.85
Adverse effects of rabies pre- and postexposure prophylaxis in 290 health-care-workers exposed to a rabies infected organ donor or transplant recipients. Infection (2007) 0.84
No evidence for a role of human herpesvirus type 8 in sarcoidosis: molecular and serological analysis. Br J Dermatol (1999) 0.84
Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements. Oncogene (1998) 0.84
HTLV-I associated primary CNS T-cell lymphoma. J Neurol Sci (1998) 0.83
Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood (2000) 0.83
Involvement of complement in B-cell, T-cell and monocyte/macrophage activation. Immunol Lett (1987) 0.83
A truncated HTLV-I envelope protein, lacking the hydrophobic membrane anchor domain, is associated with cellular membranes and virions. Virology (1994) 0.82
Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis (1991) 0.82
Enzyme-linked immunoassay to monitor the purification of, and to screen for monoclonal antibodies against, C3b receptor. Complement (1985) 0.82
Human herpesvirus DNA in prostate and semen from HIV-negative individuals in Italy. AIDS (1997) 0.81
Characterization of monoclonal antibodies to human immunodeficiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli. FEMS Microbiol Immunol (1990) 0.81
Serological discrimination between HIV-1 and HIV-2. Lancet (1988) 0.81
Probing the conformation of the human T-lymphotropic virus I envelope protein complex with monoclonal antibodies. J Gen Virol (1996) 0.80
Origin of HIV. BMJ (1989) 0.79
Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology (1988) 0.79
A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Br J Cancer (2001) 0.79
Direct demonstration of binding of aggregated mouse IgG1 to the 40-kDa Fc receptor for IgG (Fc gamma RII) in both high and low responders. Immunol Lett (1992) 0.79
Inoculation of New World primates with the human immunodeficiency virus. J Med Primatol (1989) 0.78
Herpes simplex virus type 1 and 2 in the adrenal glands: replication and histopathology. Arch Virol (1986) 0.78
[Localization of functionally important areas of the regulator protein factor H using monoclonal antibodies]. Wien Klin Wochenschr (1985) 0.77
The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant (2009) 0.77
Importance of factors H and I for the adherence of C3b-coated erythrocytes to cells. Immunobiology (1983) 0.77
Lack of evidence of HHV-8 in mature T-cell lymphoproliferative disorders. Lancet (1996) 0.77
Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry. Virus Res (2005) 0.77
HHV-8 transmission via saliva to soothe blood-sucking arthropod bites. Br J Cancer (2004) 0.77
Complement-dependent triggering of B-cells, T-cells and macrophages. Behring Inst Mitt (1987) 0.76
Antisense RNA to treat HIV infections. AIDS (1991) 0.75